{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:28:46Z","timestamp":1790378926376,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T00:00:00Z","timestamp":1380153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1472-6963-13-359","type":"journal-article","created":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T15:09:01Z","timestamp":1380208141000},"source":"Crossref","is-referenced-by-count":33,"title":["Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany"],"prefix":"10.1186","volume":"13","author":[{"given":"Bernhard","family":"Ultsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Weidemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Reinhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Siedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,26]]},"reference":[{"issue":"11\u201312","key":"2807_CR1","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s00103-012-1539-7","volume":"55","author":"S Klein","year":"2012","unstructured":"Klein S, Sch\u00f6neberg I, Krause G: Vom Zwang zur Pockenschutzimpfung zum Nationalen Impfplan. Bundesgesundheitsbl. 2012, 55 (11\u201312): 1512-1523.","journal-title":"Bundesgesundheitsbl"},{"issue":"1\u20132","key":"2807_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0264-410X(01)00276-6","volume":"20","author":"P Wutzler","year":"2001","unstructured":"Wutzler P, F\u00e4rber I, Wagenpfeil S, Bisanz H, Tischer A: Seroprevalence of varicella-zoster virus in the German population. Vaccine. 2001, 20 (1\u20132): 121-124.","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"2807_CR3","first-page":"25","volume":"14","author":"J Breuer","year":"2007","unstructured":"Breuer J, Whitley R: Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes. 2007, 14 (Suppl 2): 25-29.","journal-title":"Herpes"},{"key":"2807_CR4","first-page":"9","volume":"58","author":"RE Hope-Simpson","year":"1965","unstructured":"Hope-Simpson RE: The nature of Herpes Zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965, 58: 9-20.","journal-title":"Proc R Soc Med"},{"issue":"5","key":"2807_CR5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00063-010-1061-3","volume":"105","author":"M Wittek","year":"2010","unstructured":"Wittek M, Doerr HW, Allwinn R: Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Med Klin (Munich). 2010, 105 (5): 334-338.","journal-title":"Med Klin (Munich)"},{"issue":"Suppl 2","key":"2807_CR6","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1086\/522152","volume":"197","author":"K Schmader","year":"2008","unstructured":"Schmader K, Gnann JW, Watson CP: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008, 197 (Suppl 2): S207-S215.","journal-title":"J Infect Dis"},{"issue":"8","key":"2807_CR7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/AJP.0b013e3181eef686","volume":"26","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, Camden S, Mansi JA: A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010, 26 (8): 656-666.","journal-title":"Clin J Pain"},{"issue":"3","key":"2807_CR8","first-page":"373","volume":"54","author":"W Opstelten","year":"2008","unstructured":"Opstelten W, Eekhof J, Neven AK, Verheij T: Treatment of herpes zoster. Can Fam Physician. 2008, 54 (3): 373-377.","journal-title":"Can Fam Physician"},{"issue":"1","key":"2807_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s13671-011-0004-4","volume":"1","author":"H Forbes","year":"2012","unstructured":"Forbes H, Thomas S, Langan S: The Epidemiology and Prevention of Herpes Zoster. Curr Dermat Rep. 2012, 1 (1): 39-47.","journal-title":"Curr Dermat Rep"},{"issue":"157","key":"2807_CR10","first-page":"571","volume":"25","author":"RE Hope-Simpson","year":"1975","unstructured":"Hope-Simpson RE: Postherpetic neuralgia. J R Coll Gen Pract. 1975, 25 (157): 571-575.","journal-title":"J R Coll Gen Pract"},{"key":"2807_CR11","doi-asserted-by":"crossref","unstructured":"Jericho BG: Postherpetic neuralgia: a review. Internet Journal of Pain, Symptom Control and Palliative Care. 2010, 8 (1).","DOI":"10.5580\/124b"},{"issue":"2\u20133","key":"2807_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0304-3959(96)03122-3","volume":"67","author":"RH Dworkin","year":"1996","unstructured":"Dworkin RH, Portenoy RK: Pain and its persistence in herpes zoster. Pain. 1996, 67 (2\u20133): 241-251.","journal-title":"Pain"},{"issue":"6","key":"2807_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jpain.2005.01.359","volume":"6","author":"G Oster","year":"2005","unstructured":"Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD: Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005, 6 (6): 356-363.","journal-title":"J Pain"},{"issue":"16","key":"2807_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA: The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010, 182 (16): 1731-1736.","journal-title":"CMAJ"},{"issue":"6","key":"2807_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","volume":"23","author":"KE Schmader","year":"2007","unstructured":"Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, et al: The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007, 23 (6): 490-496.","journal-title":"Clin J Pain"},{"issue":"3","key":"2807_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1086\/421942","volume":"39","author":"J Katz","year":"2004","unstructured":"Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH: Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004, 39 (3): 342-348.","journal-title":"Clin Infect Dis"},{"issue":"23\u201324","key":"2807_CR17","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1016\/S0264-410X(01)00044-5","volume":"19","author":"WJ Edmunds","year":"2001","unstructured":"Edmunds WJ, Brisson M, Rose JD: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001, 19 (23\u201324): 3076-3090.","journal-title":"Vaccine"},{"issue":"4","key":"2807_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/00013542-199310000-00006","volume":"4","author":"E Miller","year":"1993","unstructured":"Miller E, Marshall R, Vurdien J: Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol. 1993, 4 (4): 222-230.","journal-title":"Rev Med Microbiol"},{"issue":"2","key":"2807_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S0950268801005921","volume":"127","author":"M Brisson","year":"2001","unstructured":"Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G: Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001, 127 (2): 305-314.","journal-title":"Epidemiol Infect"},{"issue":"15","key":"2807_CR20","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1001\/archinte.1995.00430150071008","volume":"155","author":"JG Donahue","year":"1995","unstructured":"Donahue JG, Choo PW, Manson JE, Platt R: The incidence of herpes zoster. Arch Intern Med. 1995, 155 (15): 1605-1609.","journal-title":"Arch Intern Med"},{"key":"2807_CR21","first-page":"1","volume-title":"Eur J Health Econ","author":"B Ultsch","year":"2012","unstructured":"Ultsch B, K\u00f6ster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O: Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2012, 1-12."},{"issue":"1","key":"2807_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/1471-2334-11-173","volume":"11","author":"B Ultsch","year":"2011","unstructured":"Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O: Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011, 11 (1): 173.","journal-title":"BMC Infect Dis"},{"key":"2807_CR23","first-page":"193","volume":"151","author":"J Schiffner-Rohe","year":"2009","unstructured":"Schiffner-Rohe J, Jow S, Lilie HM, K\u00f6ster I, Schubert I: Herpes zoster in Deutschland - Eine retrospektive Analyse von GKV-Daten. MMW Fortschr Med Originalien. 2009, 151: 193-197.","journal-title":"MMW Fortschr Med Originalien"},{"issue":"5","key":"2807_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2165\/00128071-200506050-00005","volume":"6","author":"A Volpi","year":"2005","unstructured":"Volpi A, Gross G, Hercogova J, Johnson RW: Current management of herpes zoster: the European view. Am J Clin Dermatol. 2005, 6 (5): 317-325.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"2807_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/0002512-200825120-00002","volume":"25","author":"RW Johnson","year":"2008","unstructured":"Johnson RW, Wasner G, Saddier P, Baron R: Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008, 25 (12): 991-1006.","journal-title":"Drugs Aging"},{"issue":"3","key":"2807_CR26","first-page":"255","volume":"49","author":"BS Alper","year":"2000","unstructured":"Alper BS, Lewis PR: Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia?. J Fam Pract. 2000, 49 (3): 255-264.","journal-title":"J Fam Pract"},{"issue":"6","key":"2807_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00063-010-1071-1","volume":"105","author":"M Wittek","year":"2010","unstructured":"Wittek M, Doerr HW, Allwinn R: Varicella and herpes zoster. Part 2: therapy and prevention. Med Klin (Munich). 2010, 105 (6): 399-403.","journal-title":"Med Klin (Munich)"},{"issue":"3","key":"2807_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1386-6532(03)00005-2","volume":"26","author":"G Gross","year":"2003","unstructured":"Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW: Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol. 2003, 26 (3): 277-289. discussion 291\u2013273","journal-title":"J Clin Virol"},{"issue":"22","key":"2807_CR29","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005, 352 (22): 2271-2284.","journal-title":"N Engl J Med"},{"issue":"7","key":"2807_CR30","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Levin MJ, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C: Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years. Clin Infect Dis. 2012, 54 (7): 922-928.","journal-title":"Clin Infect Dis"},{"key":"2807_CR31","unstructured":"Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged >= 50 Years [ClinicalTrials.gov Identifier NCT01165177] last update February 7, 2013. 2013, http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01165177?term=herpes+zoster&spons=GlaxosmithKline&age=12&phase=2&rank=1 ."},{"issue":"32","key":"2807_CR32","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1016\/j.vaccine.2007.04.070","volume":"25","author":"M Drummond","year":"2007","unstructured":"Drummond M, Chevat C, Lothgren M: Do we fully understand the economic value of vaccines?. Vaccine. 2007, 25 (32): 5945-5957.","journal-title":"Vaccine"},{"key":"2807_CR33","unstructured":"Gesetzliche Krankenversicherung Mitglieder,mitversicherte Angeh\u00f6rige und Krankenstand Monatswerte Januar-Mai 2013. 2013, http:\/\/bundesgesundheitsministerium.de\/fileadmin\/dateien\/Downloads\/Statistiken\/GKV\/Mitglieder_Versicherte\/KM1_Januar_Mai_2013.pdf ."},{"issue":"3","key":"2807_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3111\/13696998.2010.502854","volume":"13","author":"L Annemans","year":"2010","unstructured":"Annemans L, Bresse X, Gobbo C, Papageorgiou M: Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010, 13 (3): 537-551.","journal-title":"J Med Econ"},{"issue":"5","key":"2807_CR35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/BF03405246","volume":"99","author":"M Brisson","year":"2008","unstructured":"Brisson M: Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health. 2008, 99 (5): 383-386.","journal-title":"Can J Public Health"},{"issue":"1","key":"2807_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S0950268808000678","volume":"137","author":"A Gauthier","year":"2009","unstructured":"Gauthier A, Breuer J, Carrington D, Martin M, Remy V: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009, 137 (1): 38-47.","journal-title":"Epidemiol Infect"},{"issue":"50","key":"2807_CR37","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1016\/j.vaccine.2010.09.074","volume":"28","author":"S Gonzalez Chiappe","year":"2010","unstructured":"Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow O, Blanchon T, Hanslik T: Herpes zoster: burden of disease in France. Vaccine. 2010, 28 (50): 7933-7938.","journal-title":"Vaccine"},{"issue":"9","key":"2807_CR38","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1212\/WNL.38.9.1427","volume":"38","author":"M Max","year":"1988","unstructured":"Max M, Schafer S, Culnane M, Smoller B, Dubner R, Gracely R: Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology. 1988, 38 (9): 1427.","journal-title":"Neurology"},{"issue":"5","key":"2807_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/fampra\/19.5.471","volume":"19","author":"W Opstelten","year":"2002","unstructured":"Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA: Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002, 19 (5): 471-475.","journal-title":"Fam Pract"},{"issue":"9","key":"2807_CR40","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","volume":"27","author":"AJ van Hoek","year":"2009","unstructured":"van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ: Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009, 27 (9): 1454-1467.","journal-title":"Vaccine"},{"issue":"12","key":"2807_CR41","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.4065\/mcp.2011.0724","volume":"86","author":"BP Yawn","year":"2011","unstructured":"Yawn BP: Post-shingles neuralgia by any definition is painful, but is it PHN?. Mayo Clin Proc. 2011, 86 (12): 1141-1142.","journal-title":"Mayo Clin Proc"},{"key":"2807_CR42","unstructured":"General Methods for Assessment of the Relation of Benefits to Costs. https:\/\/www.iqwig.de\/download\/General_Methods_for_the_Assessment_of_the_Relation_of_Benefits_to_Costs.pdf ."},{"key":"2807_CR43","unstructured":"Cost estimation - working paper, Version 1.0. https:\/\/www.iqwig.de\/download\/Working_Paper_Cost_Estimation.pdf ."},{"issue":"5","key":"2807_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMcp013211","volume":"347","author":"JW Gnann Jr","year":"2002","unstructured":"Gnann JW, Whitley RJ: Clinical practice. Herpes zoster. N Engl J Med. 2002, 347 (5): 340-346.","journal-title":"N Engl J Med"},{"issue":"5","key":"2807_CR45","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00005792-198209000-00003","volume":"61","author":"MW Ragozzino","year":"1982","unstructured":"Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry HO: Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982, 61 (5): 310-316.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"2807_CR46","first-page":"1320","volume":"55","author":"HF Tseng","year":"2012","unstructured":"Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ: Herpes zoster Vaccine and the incidence of Recurrent Herpes Zoster in an immunocompetent elderly population. J Infect Dis. 2012, 55 (10): 1320-1328.","journal-title":"J Infect Dis"},{"issue":"2","key":"2807_CR47","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4065\/mcp.2010.0618","volume":"86","author":"BP Yawn","year":"2011","unstructured":"Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P: Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011, 86 (2): 88-93.","journal-title":"Mayo Clin Proc"},{"key":"2807_CR48","unstructured":"Bev\u00f6lkerung und Erwerbst\u00e4tigkeit - Sterbetafel Deutschland. https:\/\/www.destatis.de\/DE\/ZahlenFakten\/GesellschaftStaat\/Bevoelkerung\/Sterbefaelle\/Tabellen\/SterbetafelDeutschland.xls?__blob=publicationFile ."},{"key":"2807_CR49","first-page":"CD008858","volume":"10","author":"AM Gagliardi","year":"2012","unstructured":"Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG: Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2012, 10: CD008858.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"2807_CR50","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1086\/522159","volume":"197","author":"MN Oxman","year":"2008","unstructured":"Oxman MN, Levin MJ: Vaccination against Herpes Zoster and Postherpetic Neuralgia. J Infect Dis. 2008, 197 (Suppl 2): S228-S236.","journal-title":"J Infect Dis"},{"key":"2807_CR51","unstructured":"FDA: FDA Clinical Briefing Document for Merck & Co., Inc. Zoster vaccine live (Oka\/Merck) Zostavax\u2122. Vaccines and Related Biological Products Advisory Committee. Edited by: US-Food-and-Drug-Administration. 2005"},{"key":"2807_CR52","volume-title":"ICAAC\/IDSA: 2008; Durham","author":"K Schmader","year":"2008","unstructured":"Schmader K, Oxman M, Levin M, Betts R, Morrison V, Gelb L, Johnson G, Zhang J, Li X, Annunziato P: Persistence of Zoster Vaccine Efficacy. ICAAC\/IDSA: 2008; Durham. 2008"},{"key":"2807_CR53","volume-title":"Clin Infect Dis","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, et al: Persistence of the Efficacy of Zoster Vaccine in the Shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012"},{"issue":"3","key":"2807_CR54","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.vaccine.2011.10.036","volume":"30","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P: Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012, 30 (3): 675-684.","journal-title":"Vaccine"},{"issue":"17","key":"2807_CR55","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1016\/j.vaccine.2011.09.079","volume":"30","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P: Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?. Vaccine. 2012, 30 (17): 2795-2800.","journal-title":"Vaccine"},{"issue":"49","key":"2807_CR56","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","volume":"25","author":"JM Pellissier","year":"2007","unstructured":"Pellissier JM, Brisson M, Levin MJ: Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007, 25 (49): 8326-8337.","journal-title":"Vaccine"},{"key":"2807_CR57","volume-title":"Noninfluenza Vaccination Coverage Among Adults \u2014 United States","author":"MMWR","year":"2011","unstructured":"MMWR: Noninfluenza Vaccination Coverage Among Adults \u2014 United States. 2011, http:\/\/www.cdc.gov\/mmwr\/pdf\/wk\/mm62e0129.pdf ."},{"key":"2807_CR58","unstructured":"Epidemiologisches Bulletin. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2002\/Ausgabenlinks\/16_02.pdf?__blob=publicationFile ."},{"key":"2807_CR59","unstructured":"Lauer-Taxe online - Preisinfo: ZOSTAVAX. 2010, http:\/\/www2.lauer-fischer.de\/home\/ ."},{"key":"2807_CR60","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2008","unstructured":"Briggs A, Claxton K, Sculpher M: Decision modelling for health economic evaluation. 2008, Oxford: Oxford University Press"},{"issue":"2","key":"2807_CR61","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/s-2005-867061","volume":"56","author":"A Hinz","year":"2006","unstructured":"Hinz A, Klaiberg A, Brahler E, Konig HH: [The quality of life questionnaire EQ-5D: modelling and norm values for the general population]. Psychother Psychosom Med Psychol. 2006, 56 (2): 42-48.","journal-title":"Psychother Psychosom Med Psychol"},{"issue":"4","key":"2807_CR62","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/hec.985","volume":"14","author":"K Claxton","year":"2005","unstructured":"Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005, 14 (4): 339-347.","journal-title":"Health Econ"},{"issue":"13","key":"2807_CR63","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","volume":"22","author":"R Welte","year":"2004","unstructured":"Welte R, Feenstra T, Jager H, Leidl R: A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004, 22 (13): 857-876.","journal-title":"Pharmacoeconomics"},{"key":"2807_CR64","volume-title":"Reconciling Social and Industrial Goals","author":"S Jacobzone","year":"2000","unstructured":"Jacobzone S: Pharmaceutical Policies in OECD Countries. Reconciling Social and Industrial Goals. Edited by: 40 OLMaSPOPN. 2000, Paris: OECD"},{"key":"2807_CR65","volume-title":"J Clin Gerontol Geriatr","author":"G Mick","year":"2013","unstructured":"Mick G, Hans G: Postherpetic neuralgia in Europe: The scale of the problem and outlook for the future. J Clin Gerontol Geriatr. 2013"},{"key":"2807_CR66","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1016\/j.pain.2013.04.015","volume":"10","author":"H Reda","year":"2013","unstructured":"Reda H, Greene K, Rice FL, Rowbotham MC, Petersen KL: Natural History of Herpes Zoster: Late follow-up 3.9 yrs (n= 43) and 7.7 yrs (n= 10). PAIN. 2013, 10: 2227-2233.","journal-title":"PAIN"},{"issue":"1","key":"2807_CR67","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1472-6963-10-237","volume":"10","author":"A van Lier","year":"2010","unstructured":"van Lier A, van Hoek AJ, Opstelten W, Boot H, de Melker H: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010, 10 (1): 237.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"2807_CR68","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.vaccine.2012.12.067","volume":"31","author":"PT De Boer","year":"2013","unstructured":"De Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ: Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013, 31 (9): 1276-1283.","journal-title":"Vaccine"},{"issue":"7","key":"2807_CR69","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4161\/hv.7.7.15573","volume":"7","author":"TD Szucs","year":"2011","unstructured":"Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel JP, Fendl A, Bresse X: Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011, 7 (7): 749-756.","journal-title":"Hum Vaccin"},{"issue":"3","key":"2807_CR70","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1586\/erp.13.19","volume":"13","author":"X Bresse","year":"2013","unstructured":"Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A: Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2013, 13 (3): 393-406.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"2807_CR71","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1478-7547-8-7","volume":"8","author":"L Moore","year":"2010","unstructured":"Moore L, Remy V, Martin M, Beillat M, McGuire A: A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Effectiveness and Resource Allocation. 2010, 8 (1): 7.","journal-title":"Cost Effectiveness and Resource Allocation"},{"issue":"5","key":"2807_CR72","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/0003-4819-145-5-200609050-00004","volume":"145","author":"J Hornberger","year":"2006","unstructured":"Hornberger J, Robertus K: Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006, 145 (5): 317-325.","journal-title":"Ann Intern Med"},{"issue":"10","key":"2807_CR73","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1086\/514342","volume":"44","author":"MB Rothberg","year":"2007","unstructured":"Rothberg MB, Virapongse A, Smith KJ: Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007, 44 (10): 1280-1288.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2807_CR74","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4161\/hv.4.3.5686","volume":"4","author":"M Brisson","year":"2008","unstructured":"Brisson M, Pellissier JM, Camden S, Quach C, De Wals P: The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008, 4 (3): 238-245.","journal-title":"Hum Vaccin"},{"issue":"12","key":"2807_CR75","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2165\/11314010-000000000-00000","volume":"27","author":"M Najafzadeh","year":"2009","unstructured":"Najafzadeh M, Marra CA, Galanis E, Patrick DM: Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009, 27 (12): 991-1004.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2807_CR76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s40273-012-0020-7","volume":"31","author":"TD Szucs","year":"2013","unstructured":"Szucs TD, Pfeil AM: A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013, 31 (2): 125-136.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"2807_CR77","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jpain.2004.06.001","volume":"5","author":"PM Coplan","year":"2004","unstructured":"Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, et al: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004, 5 (6): 344-356.","journal-title":"J Pain"},{"issue":"8","key":"2807_CR78","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0895-4356(98)00036-5","volume":"51","author":"MV Bala","year":"1998","unstructured":"Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B: Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. Journal of clinical epidemiology. 1998, 51 (8): 667-676.","journal-title":"Journal of clinical epidemiology"},{"key":"2807_CR79","first-page":"3","volume":"6","author":"JM Graf Von Der Schulenburg","year":"1998","unstructured":"Graf Von Der Schulenburg JM, Claes C, Greiner W, et al: Die deutsche Version des EuroQol-Fragebogens. Zeitschrift f\u00fcr Gesundheitswissenschaften. 1998, 6: 3-20.","journal-title":"Zeitschrift f\u00fcr Gesundheitswissenschaften"},{"key":"2807_CR80","volume-title":"Gesundheitswesen","author":"J Hoebel","year":"2013","unstructured":"Hoebel J, Kuntz B, Muters S, Lampert T: Subjective Social Status and Health-Related Quality of Life among Adults in Germany. Gesundheitswesen. 2013"},{"issue":"3","key":"2807_CR81","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-2005-857991","volume":"67","author":"HH Konig","year":"2005","unstructured":"Konig HH, Bernert S, Angermeyer MC: Health status of the German population: results of a representative survey using the EuroQol questionnaire. Gesundheitswesen. 2005, 67 (3): 173-182.","journal-title":"Gesundheitswesen"},{"issue":"8\u20139","key":"2807_CR82","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1055\/s-0029-1239508","volume":"72","author":"A Mielck","year":"2010","unstructured":"Mielck A, Vogelmann M, Schweikert B, Leidl R: Health status of adults in Germany: results from a representative survey using the EuroQol 5D (EQ-5D). Gesundheitswesen. 2010, 72 (8\u20139): 476-486.","journal-title":"Gesundheitswesen"},{"issue":"1","key":"2807_CR83","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1471-2334-12-110","volume":"12","author":"J Pierik","year":"2012","unstructured":"Pierik J, Gumbs P, Fortanier S, Van Steenwijk P, Postma M: Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis. 2012, 12 (1): 110.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2807_CR84","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1471-2334-10-230","volume":"10","author":"L Gialloreti","year":"2010","unstructured":"Gialloreti L, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A: Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010, 10 (1): 230.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"2807_CR85","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/1471-2334-11-302","volume":"11","author":"A Cebrian-Cuenca","year":"2011","unstructured":"Cebrian-Cuenca A, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis. 2011, 11 (1): 302.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2807_CR86","doi-asserted-by":"publisher","first-page":"854","DOI":"10.4161\/hv.23412","volume":"9","author":"T Vesikari","year":"2013","unstructured":"Vesikari T, Hardt R, R\u00fcmke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A: Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax\u00ae) in individuals aged \u2265 70 years: a randomized study of a single dose vs. two different two-dose schedules. Human Vaccines & Immunotherapeutics. 2013, 9 (4): 854-860.","journal-title":"Human Vaccines & Immunotherapeutics"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-13-359\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-13-359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-13-359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-13-359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,6]],"date-time":"2022-03-06T23:16:59Z","timestamp":1646608619000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-13-359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,26]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2807"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-13-359","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,26]]},"article-number":"359"}}